We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+11.72%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$3.39B
AUM Growth
-$174M
Cap. Flow
-$28.5M
Cap. Flow %
-0.84%
Top 10 Hldgs %
46.4%
Holding
115
New
19
Increased
20
Reduced
20
Closed
16

Top Buys

Rank Stock Value
1
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$127M
2
ACLX
Arcellx
ACLX
+$37.7M
3
SNY icon
Sanofi
SNY
+$37.4M
4
IOVA icon
Iovance Biotherapeutics
IOVA
+$37M
5
APLS
Apellis Pharmaceuticals
APLS
+$32M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$109M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$50.4M
3
VRNA
Verona Pharma
VRNA
+$46.4M
4
ALBO
Albireo Pharma Inc
ALBO
+$38M
5
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$31.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.49%
2 Financials 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FOLD
1
DELISTED
Amicus Therapeutics
FOLD
$307M 9.06%
27,662,917
+20,000
+0.1% +$247K
RETA
2
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$197M 5.82%
+2,169,276
New +$127M
AMLX icon
3
Amylyx Pharmaceuticals
AMLX
$2.19B
$177M 5.23%
6,034,644
-53,689
-0.9% -$1.87M
CERE
4
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$159M 4.69%
6,511,727
– –
MDGL icon
5
Madrigal Pharmaceuticals
MDGL
$12.5B
$158M 4.65%
650,562
-81,370
-11% -$22.2M
RXDX
6
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$137M 4.03%
1,272,694
+60,000
+5% +$6.91M
ACLX
7
DELISTED
Arcellx
ACLX
$118M 3.49%
3,841,739
+1,243,434
+48% +$37.7M
LIAN
8
DELISTED
LianBio American Depositary Shares
LIAN
$113M 3.33%
57,558,451
– –
ALDX icon
9
Aldeyra Therapeutics
ALDX
$95.3M
$113M 3.33%
11,350,085
– –
IOVA icon
10
Iovance Biotherapeutics
IOVA
$2.03B
$93.7M 2.77%
15,339,735
+5,367,955
+54% +$37M
INBX
11
DELISTED
Inhibrx, Inc. Common Stock
INBX
$68.2M 2.01%
3,615,383
+301,600
+9% +$7.01M
XENE icon
12
Xenon Pharmaceuticals
XENE
$6.08B
$65.6M 1.94%
1,832,174
-89,099
-5% -$3.29M
BMRN icon
13
BioMarin Pharmaceuticals
BMRN
$11.8B
$65.4M 1.93%
673,060
+166,579
+33% +$17.3M
TMCI icon
14
Treace Medical Concepts
TMCI
$260M
$61.5M 1.82%
2,442,250
+495,847
+25% +$11.6M
NUVL
15
DELISTED
Nuvalent
NUVL
$60M 1.77%
2,300,048
+45,041
+2% +$1.33M
MRTX
16
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$58.5M 1.73%
1,574,134
-617,291
-28% -$27.8M
CRNX icon
17
Crinetics Pharmaceuticals
CRNX
$8.87B
$57.1M 1.69%
3,554,887
-484,389
-12% -$8.96M
VRNA
18
DELISTED
Verona Pharma
VRNA
$54.9M 1.62%
2,733,790
-2,146,929
-44% -$46.4M
SWTX
19
DELISTED
SpringWorks Therapeutics
SWTX
$53.5M 1.58%
2,079,352
-538,339
-21% -$15.7M
OBIO icon
20
Orchestra BioMed
OBIO
$228M
$44.6M 1.32%
+2,278,226
New +$26.4M
VRDN icon
21
Viridian Therapeutics
VRDN
$2.17B
$44.2M 1.3%
1,736,386
+515,811
+42% +$16.5M
PCVX icon
22
Vaxcyte
PCVX
$7.58B
$43.9M 1.29%
1,170,000
– –
RAPT
23
DELISTED
RAPT Therapeutics
RAPT
$42.1M 1.24%
286,451
+61,582
+27% +$12.5M
SNY icon
24
Sanofi
SNY
$108B
$41.8M 1.23%
+768,101
New +$37.4M
ADMA icon
25
ADMA Biologics
ADMA
$2.01B
$39.4M 1.16%
11,900,255
– –
1
2 3 4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q1 2023 Portfolio in Review

As of Q1 2023, Perceptive Advisors held 115 positions worth $3.39B, down 4.9% from $3.56B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Perceptive Advisors's Q1 2023 filing shows 19 new, 20 increased, 20 reduced and 16 closed positions. Its largest new stake was Reata Pharmaceuticals, Inc. Class A Common Stock: 2,169,276 shares worth $197M. The largest sale was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $109M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 97% a quarter earlier, followed by Financials.

  • Perceptive Advisors's largest Q1 2023 buy was Reata Pharmaceuticals, Inc. Class A Common Stock: 2,169,276 shares worth $197M.
  • Perceptive Advisors added most to Arcellx in Q1 2023, an estimated $37.7M increase.
  • Perceptive Advisors's biggest Q1 2023 reduction was Sarepta Therapeutics, cutting an estimated $50.4M.
  • Perceptive Advisors fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2023, selling an estimated $109M.
  • Perceptive Advisors's ten largest holdings make up 46% of its $3.39B portfolio in Q1 2023.
  • Perceptive Advisors opened 19 new positions and closed 16 in Q1 2023.
  • Perceptive Advisors's portfolio value fell 4.9% quarter-over-quarter to $3.39B.

Based on Perceptive Advisors's 13F filing for Q1 2023, filed 15 May 2023.